Scientific article
Open access

Long-term levels of protection of different types of immunity against the Omicron variant : a rapid literature review

Published inSwiss medical weekly, vol. 154, 3732
Publication date2024-05-06
First online date2024-05-06

Introduction: With the emergence of newer SARS-CoV-2 variants and their substantial effects on the levels and duration of protection against infection, an understanding of these characteristics of the protection conferred by humoral and cellular immunity can aid in the proper development and implementation of vaccine and safety guidelines.

Methods: We conducted a rapid literature review and searched five electronic databases weekly from 1 November 2021 to 30 September 2022. Studies that assessed the humoral or cellular immunity conferred by infection, vaccination or a hybrid (combination of both) in adults and risk groups (immunocompromised and older populations) were identified. Studies were eligible when they reported data on immunological assays of COVID-19 (related to vaccination and/or infection) or the effectiveness of protection (related to the effectiveness of vaccination and/or infection).

Results: We screened 5103 studies and included 205 studies, of which 70 provided data on the duration of protection against SARS-CoV-2 infection. The duration of protection of adaptive immunity was greatly impacted by Omicron and its subvariants: levels of protection were low by 3-6 months from exposure to infection/vaccination. Although more durable, cellular immunity also showed signs of waning by 6 months. First and second mRNA vaccine booster doses increased the levels of protection against infection and severe disease from Omicron and its subvariants but continued to demonstrate a high degree of waning over time.

Conclusion: All humoral immunities (infection-acquired, vaccine-acquired and hybrid) waned by 3-6 months. Cellular immunity was more durable but showed signs of waning by 6 months. Hybrid immunity had the highest magnitude of protection against SARS-CoV-2 infection. Boosting may be recommended as early as 3-4 months after the last dose, especially in risk groups.

  • Humans
  • COVID-19 / prevention & control
  • COVID-19 / immunology
  • SARS-CoV-2 / immunology
  • COVID-19 Vaccines / immunology
  • Immunity, Cellular / immunology
  • Immunity, Humoral / immunology
  • Immunization, Secondary
  • Vaccination
Citation (ISO format)
RODRIGUEZ VELÁSQUEZ, Sabina et al. Long-term levels of protection of different types of immunity against the Omicron variant : a rapid literature review. In: Swiss medical weekly, 2024, vol. 154, p. 3732. doi: 10.57187/s.3732
Main files (1)
Article (Published version)
ISSN of the journal1424-3997

Technical informations

Creation05/23/2024 9:14:07 AM
First validation06/11/2024 9:23:54 AM
Update time06/11/2024 9:23:54 AM
Status update06/11/2024 9:23:54 AM
Last indexation06/11/2024 9:24:13 AM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack